ÂÜÀòÂÒÂ×

Francois Bertelli is an experienced biopharmaceutical professional serving as the Head of Antibody Research at 272BIO Limited since July 2022. Prior to this role, Bertelli held positions including Executive Director at FSB Biopharma Consulting, and Head of Platform Development at Avvinity Therapeutics Limited. Bertelli has extensive expertise in monoclonal antibody discovery, humanization, and development, particularly with antibody-drug conjugates. Previous roles include Principal Scientist Biotherapeutics at LifeArc, Head of Biology at Spirogen (MedImmune), and Senior Principal Scientist at Pfizer, where responsibilities encompassed high-throughput screening and drug discovery project management. Bertelli earned a Ph.D. in Enzymology, Physico-chemistry, and Protein Production from Paris-Sud University and holds additional degrees in biochemistry and enzymology.